Advantages EmboLog® S

1. Good tolerability

(Haubold et al. 2020; Orlacchio et al. 2019)

2. Optimum degradation time

(Wiggermann et al. 2012)

3. Significant increase of the area of necrosis within the tumor tissue

(Ziemann et al. 2019)

4. Repeatable TACE

(Gross et al. 2019, Gruber-Rouh et al. 2018)

5. Established and clinically proved particle characteristics:

The production of degradable starch microspheres has been established at Serumwerk Bernburg AG since 2004. The developed and manufactured device, distributed by our former, exclusive distribution partner under its trademark EmboCept®*, was characterized by homogeneous, spherical particles that did not show any relevant deformations during catheter passage (Paprottka et al. 2016). The microspheres were optimized with regard to degradation (Wiggermann et al. 2012). The developed, manufactured and clinically proved starch microspheres are now distributed under the new product name EmboLog® S directly from Serumwerk Bernburg AG.

Why DSM-TACE?

  • Flexibility of the TACE-treatment:
N

No limitation concerning active ingredient for DSM-TACE

N

Combinable with further treatment methods

  • Use of a starch-based polymer

Bibliography of starch microspheres from Serumwerk Bernburg AG used for DSM-TACE

 

Preloader

  • Haubold et al. [33] Gross et al. [34]

    Haubold et al. [33]
    Gross et al. [34]

  • Larsen et al. [28] Lindgaard et al. [29] Lucatelli et al. [30] Georg et al. [31]

    Larsen et al. [28]
    Lindgaard et al. [29]
    Lucatelli et al. [30]
    Orlacchio et al. [31]
    Georg et al. [32]

  • Vogl et al. [22,23] Schicho et al. [24] Gruber-Rouh et al. [25,26] Iezzi et al. [27]

    Vogl et al. [22,23]
    Schicho et al. [24]
    Gruber-Rouh et al. [25,26]
    Iezzi et al. [27]

  • Schicho et al.[21]

    Schicho et al. [21]

     

  • Schicho et al. [20]

    Schicho et al. [20]

     

  • Orlacchio et al. [19]

    Orlacchio et al. [19]

     

  • Vogl et al. [17] Niessen et al. [18]

    Vogl et al. [17]
    Niessen et al. [18]

  • Farshid et al. [11] Vogl et al. [12] Heibl et al. [13] Eichler et al. [14] Wiggermann et al. [15] Gruber-Rough et al. [16]

    Farshid et al. [11]
    Vogl et al. [12]
    Heibl et al. [13]
    Eichler et al. [14]
    Wiggermann et al. [15]
    Gruber-Rouh et al. [16]

  • Vogl et al. [8,9] Wiggermann et al. [10]

    Vogl et al. [8,9]
    Wiggermann et al. [10]

  • Vogl et al. [6] Azizi et al. [7]

    Vogl et al. [6]
    Azizi et al. [7]

  • Vogl et al. [3,4,5]

    Vogl et al. [3,4,5]

     

  • Nabil et al. [2]

  • Vogl et al. [1]

     

*trademark of Magle PharmaCept GmbH

complete list of references